CL2014002706A1 - Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación. - Google Patents

Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación.

Info

Publication number
CL2014002706A1
CL2014002706A1 CL2014002706A CL2014002706A CL2014002706A1 CL 2014002706 A1 CL2014002706 A1 CL 2014002706A1 CL 2014002706 A CL2014002706 A CL 2014002706A CL 2014002706 A CL2014002706 A CL 2014002706A CL 2014002706 A1 CL2014002706 A1 CL 2014002706A1
Authority
CL
Chile
Prior art keywords
phospholipid
pain
joint
treatment
active agent
Prior art date
Application number
CL2014002706A
Other languages
English (en)
Inventor
Richard Wolf Garraway
Michael Earl
Saruhan Yurdakul
Nicolas Baverstock
Original Assignee
Sequessome Technology Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequessome Technology Holdings Ltd filed Critical Sequessome Technology Holdings Ltd
Publication of CL2014002706A1 publication Critical patent/CL2014002706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2014002706A 2012-04-12 2014-10-08 Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación. CL2014002706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1206486.1A GB201206486D0 (en) 2012-04-12 2012-04-12 Vesicular formulations and uses thereof

Publications (1)

Publication Number Publication Date
CL2014002706A1 true CL2014002706A1 (es) 2015-04-24

Family

ID=46208989

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002706A CL2014002706A1 (es) 2012-04-12 2014-10-08 Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación.

Country Status (26)

Country Link
US (3) US20150065461A1 (es)
EP (1) EP2836203B1 (es)
JP (1) JP2015512926A (es)
KR (1) KR102204725B1 (es)
CN (1) CN104363894B (es)
AU (1) AU2013246822A1 (es)
BR (1) BR112014025507B1 (es)
CA (1) CA2870111A1 (es)
CL (1) CL2014002706A1 (es)
CO (1) CO7141430A2 (es)
DK (1) DK2836203T3 (es)
EA (1) EA039626B1 (es)
ES (1) ES2916803T3 (es)
GB (2) GB201206486D0 (es)
HR (1) HRP20220700T1 (es)
HU (1) HUE058972T2 (es)
IL (1) IL234862A0 (es)
IN (1) IN2014DN08259A (es)
LT (1) LT2836203T (es)
MX (1) MX2014012198A (es)
PH (1) PH12014502079A1 (es)
PL (1) PL2836203T3 (es)
PT (1) PT2836203T (es)
SG (1) SG11201406251VA (es)
SI (1) SI2836203T1 (es)
WO (1) WO2013153221A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201505532D0 (en) * 2015-03-31 2015-05-13 Sequessome Technology Holdings Ltd Formulations
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
BR112020003767B1 (pt) * 2017-08-22 2023-10-10 Moebius Medical Ltd Composição farmacêutica que compreende lipossomas e uso da dita composição para tratar dor ou irritação em uma articulação
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
CN110314137B (zh) * 2018-03-30 2022-04-05 北京泰德制药股份有限公司 一种含有脂质囊泡的冻干制剂
KR102912060B1 (ko) 2021-09-17 2026-01-14 서울대학교산학협력단 골관절염 예방 또는 치료용 약학 조성물 및 건강기능식품
CA3266614A1 (en) 2023-01-19 2024-07-25 Moebius Medical Ltd. LONG-ACTING LIPOSOMAL COMPOSITION FOR THE TREATMENT OF PAIN IN JOINT DISORDERS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509202A (ja) * 1992-07-08 1996-10-01 ディアノルム―ゲレーテ・ゲー・マイエルホファー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リポソーム、それを調製する方法及び薬調製におけるその用途
AUPN723395A0 (en) * 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
WO2002096435A2 (en) * 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
US7115666B2 (en) * 2002-10-15 2006-10-03 Renovis, Inc. Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
CA2664944C (en) * 2006-09-28 2016-06-14 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
JP2012528846A (ja) * 2009-06-03 2012-11-15 マヨ、ジョン、チャールズ 深部組織の痛みを治療するための製剤
GB2486371A (en) * 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
EP2340819A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising venlafaxine and celecoxib in the treatment of pain
US9125786B2 (en) * 2011-03-31 2015-09-08 Phillip Anthony FEMANO Method and device to alleviate carpal tunnel syndrome and dysfunctions of other soft tissues
EP2971075B1 (en) * 2013-03-13 2018-08-15 Roche Diagnostics GmbH Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene

Also Published As

Publication number Publication date
KR102204725B1 (ko) 2021-01-19
GB2515439A (en) 2014-12-24
SG11201406251VA (en) 2014-10-30
GB2515439B (en) 2017-08-23
HUE058972T2 (hu) 2022-09-28
EA201491583A1 (ru) 2015-05-29
KR20150008869A (ko) 2015-01-23
PT2836203T (pt) 2022-06-15
US20150065461A1 (en) 2015-03-05
US20170128473A1 (en) 2017-05-11
EP2836203A1 (en) 2015-02-18
CA2870111A1 (en) 2013-10-17
CN104363894A (zh) 2015-02-18
ES2916803T3 (es) 2022-07-06
WO2013153221A1 (en) 2013-10-17
LT2836203T (lt) 2022-06-10
SI2836203T1 (sl) 2022-07-29
JP2015512926A (ja) 2015-04-30
EP2836203B1 (en) 2022-03-09
BR112014025507A2 (pt) 2017-08-08
PH12014502079A1 (en) 2014-12-10
IL234862A0 (en) 2014-12-31
HRP20220700T1 (hr) 2022-07-08
CN104363894B (zh) 2016-11-23
PL2836203T3 (pl) 2022-07-11
AU2013246822A1 (en) 2014-10-16
EA039626B1 (ru) 2022-02-17
GB201206486D0 (en) 2012-05-30
BR112014025507B1 (pt) 2022-01-04
MX2014012198A (es) 2015-06-04
US20210393655A1 (en) 2021-12-23
GB201419074D0 (en) 2014-12-10
IN2014DN08259A (es) 2015-05-15
CO7141430A2 (es) 2014-12-12
DK2836203T3 (da) 2022-06-07

Similar Documents

Publication Publication Date Title
IL239923A0 (en) Solid solution compositions and use in cardiovascular disease
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112012031194A2 (pt) derivados de cisteamina e seu uso no tratamento de ehna
LT3216448T (lt) Paraziticidinės peroralinės veterinarinės kompozicijos, apimančios sisteminio poveikio veikliuosius agentus, būdai ir jų panaudojimas
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
CO6480985A2 (es) Formulaciones para el tratamiento del dolor tisular profundo
CL2015000499A1 (es) Uso de un agente farmacéuticamente aceptable que elimina el antígeno de superficie de la hepatitis b de la sangre y un segundo agente que estimula la función inmunitaria, para tratar hepatitis b o coinfección hepatitis b/hepatitis d; y composición que comprende ambos agentes.
CL2013001250A1 (es) Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion.
MA50358A (fr) Sémaglutide en thérapie médicale
CL2015001869A1 (es) Composición inyectable acuosa de diclofenaco en una solucion de eter monoetilico de dietilenglicol y agua; metodo de preparacion; y uso en el tratamiento o prevencion del dolor y/o condiciones inflamatorias como dolor de cabeza, dolor de garganta, entre otras.
IL234862A0 (en) Vascular formulations and their use for the treatment of pain or reduced mobility of a joint
SG10201704712QA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
ES2811674R1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
MX377510B (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
EA201390287A1 (ru) Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
ZA201504783B (en) Cosmetic or dermatological composition comprising a merocyanine and a uva-screening agent of the amino-substituted 2-hydroxybenzophenone type and/or a hydrophilic organic uva-screening agent
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
CL2013002322A1 (es) Uso de una composicion que comprende fentanilo, un intensificador de la penetracion y un liquido volatirl para preparar un medicamenti util en el tratamiento del dolor.
CO7240380A2 (es) Composiciones líquidas orales pediátricas que contienen nepadutant
ITUB20153104A1 (it) Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease